Symberix Co-Founder Gives Keynote Address at AACR Conference
Orlando, FL (February 21, 2020) - Symberix co-founder Matthew Redinbo gave the keynote address at the AACR Microbiome, Viruses, and Cancer conference on Friday, February 21, 2020. The special conference covers the contribution of bacterial, viral, and fungal pathogens to the development of cancers, as well as the impact of the microbiome on cancer therapy. Dr. Redinbo’s keynote, titled “Molecular control of the gut microbiome to improve cancer chemotherapy”, highlighted the importance of the gut microbiome as a novel drug target to improve the efficacy and tolerability of chemotherapy.
-
RT @AmerUnderground: We've done so much work to ensure our spaces are clean and promote social distance and as a result of that, we've s… https://t.co/gQxpnx2Ugr -
RT @misprobiotech: Great work coming out of @TheRTP from the @symberix team. #innovation #preclinical #drugdevelopment https://t.co/TdddqYJxdY
-
Symberix is hiring! Join our team of enthusiastic scientists working to develop a novel class of microbiome-targeti… https://t.co/nI7fcUAOHt
-
RT @NCIsbir: NCI #SBIRfunded @symberix’s work focuses on eliminating harmful microbial activity in the gut without killing benef… https://t.co/YLjqys7BMU
-
RT @microviable: Today in #Microbiome Connect https://t.co/Q34lA19dVI On demand: Imke Mulder @4dpharmaplc,Assaf Oron @BiomX_Inc,Bre… https://t.co/ODbhOh1wqg
-
"The end result could be drugs that are less toxic, as well as better predictions about how patients respond to med… https://t.co/JqUJtYHh9B
-
Thanks, @grant_engine! We are excited to bring this important research one step closer to the clinic. https://t.co/7LdklkvjdG
-
Symberix is developing bacteria-targeted small molecules that prevent the GI toxicity of many common medications. F… https://t.co/0JAmAsXnYB
-
A recent article in @sciam highlights @symberix's work in the emerging field of #pharmacomicrobiomics -- the study… https://t.co/yfBCxLd6sf
-
RT @AACR: Matthew Redinbo gives tonight’s keynote: Molecular control of the gut microbiome to improve cancer chemotherapy.… https://t.co/pIUWoGbigz
Symberix, Inc. is a biopharmaceutical company focused on developing the first generation of gut microbiome-targeting drugs to treat lower GI disorders. Gut microbes express numerous proteins, including a family of bacterial β-glucuronidase enzymes capable of generating toxic metabolites of many common medications in the lower GI tract. Symberix is developing bacterial β-glucuronidase inhibitors as adjunctive therapy to mitigate drug-induced toxicities and is exploring their use as monotherapy for other lower GI disorders, such as inflammatory bowel disease. Symberix’s internal team and external advisors have a deep understanding of the biology of the gut microbiome, and extensive drug discovery and clinical development experience.
Contact:
Greg Mossinghoff
Chief Business Officer
Symberix, Inc.
Greg.Mossinghoff@Symberix.com